Radioactive iodine therapy improves overall survival outcome in oncocytic carcinoma of the thyroid by reducing death risks from noncancer causes: A competing risk analysis of 4641 patients.
1/5 보강
[BACKGROUND] Oncocytic carcinoma of the thyroid (OCA) is an independent type of thyroid cancer.
APA
Zhang K, Wang X, et al. (2024). Radioactive iodine therapy improves overall survival outcome in oncocytic carcinoma of the thyroid by reducing death risks from noncancer causes: A competing risk analysis of 4641 patients.. Head & neck, 46(10), 2550-2568. https://doi.org/10.1002/hed.27758
MLA
Zhang K, et al.. "Radioactive iodine therapy improves overall survival outcome in oncocytic carcinoma of the thyroid by reducing death risks from noncancer causes: A competing risk analysis of 4641 patients.." Head & neck, vol. 46, no. 10, 2024, pp. 2550-2568.
PMID
38572629 ↗
Abstract 한글 요약
[BACKGROUND] Oncocytic carcinoma of the thyroid (OCA) is an independent type of thyroid cancer. Radioactive iodine (RAI) therapy was frequently administered to OCA patients, but its contribution to improving survival is indefinite.
[METHODS] 4641 OCA patients from 2000 to 2018 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Cox proportional hazard regression and competing risk analysis were applied.
[RESULTS] Tumor size, SEER stage, primary surgery, and neck dissection were prognostic factors for cancer-specific survival. The results of competing risk analysis demonstrated that age over 55 years dramatically increased non-OCA death risks. Treatments that improve non-OCA survival (including total thyroidectomy, RAI therapy, and systemic therapy) should be recommended in OCA patients older than 55 years of age. Neck lymphadenectomy should not be recommended for OCA, since the metastatic lymph node ratio was low (about 3%).
[CONCLUSIONS] RAI therapy can improve survival in OCA by reducing noncancer death risks.
[METHODS] 4641 OCA patients from 2000 to 2018 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Cox proportional hazard regression and competing risk analysis were applied.
[RESULTS] Tumor size, SEER stage, primary surgery, and neck dissection were prognostic factors for cancer-specific survival. The results of competing risk analysis demonstrated that age over 55 years dramatically increased non-OCA death risks. Treatments that improve non-OCA survival (including total thyroidectomy, RAI therapy, and systemic therapy) should be recommended in OCA patients older than 55 years of age. Neck lymphadenectomy should not be recommended for OCA, since the metastatic lymph node ratio was low (about 3%).
[CONCLUSIONS] RAI therapy can improve survival in OCA by reducing noncancer death risks.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Iodine Radioisotopes
- Middle Aged
- Male
- Female
- Thyroid Neoplasms
- SEER Program
- Adult
- Aged
- Risk Assessment
- Adenoma
- Oxyphilic
- Thyroidectomy
- Cause of Death
- Proportional Hazards Models
- Retrospective Studies
- Survival Analysis
- Survival Rate
- Neck Dissection
- competing risk analysis
- neck dissection
- oncocytic carcinoma of the thyroid
- radioactive iodine
- survival analysis
같은 제1저자의 인용 많은 논문 (5)
- NPM1 Mediates mRNA Sorting into Extracellular Vesicles via Specific RNA Motif Binding and Phase Separation.
- PSMA-Targeting Macrophage Membrane-Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer.
- DMBX1 expression in colon cancer and its impact on prognosis and the tumor microenvironment.
- Objective value of the apparent diffusion coefficient (ADC) map from ultrahigh b-value diffusion-weighted imaging (DWI) in 3T MRI as a non-invasive predictor for Gleason score in prostate cancer.
- Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.